Novo Nordisk A/S (NYSE:NVO) shares traded down 1.2% on Monday . The stock traded as low as $45.36 and last traded at $45.80, with a volume of 3,972,600 shares traded. The stock had previously closed at $46.34.

Several analysts have recently issued reports on NVO shares. Zacks Investment Research lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Monday, July 4th. Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Wednesday, August 3rd. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “equal weight” rating in a report on Thursday. Goldman Sachs Group Inc. lowered Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. Finally, HSBC raised Novo Nordisk A/S from a “reduce” rating to a “hold” rating in a report on Wednesday, August 31st. Four research analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $63.50.

The firm has a market cap of $116.16 billion and a price-to-earnings ratio of 21.44. The firm’s 50 day moving average is $50.68 and its 200-day moving average is $53.54.

The firm also recently disclosed a dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were given a $0.326 dividend. The ex-dividend date was Thursday, August 11th.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.